Our findings are consistent with the literature showing that MOGAD has a lower clinical myelitis incidence with a smaller chronic lesion burden (7) and a lower impact of chronic pain syndromes than AQP4-IgG + NMOSD (14). This evidence concerns the gene AQP4 and myelitis.